Oncometabolites in Pancreatic Cancer: Strategies and Its Implications

Overview

Journal World J Exp Med

Publisher Baishideng Publishing Group

Specialty Biomedical Engineering

Date 2024 Dec 23

PMID 39713078

Authors

Arunima Maiti

Susmita Mondal

Sounetra Choudhury

Arnab Bandopadhyay

Sanghamitra Mukherjee

Nilabja Sikdar

Affiliations

Soon will be listed here.

Abstract

Pancreatic cancer (PanCa) is a catastrophic disease, being third lethal in both the genders around the globe. The possible reasons are extreme disease invasiveness, highly fibrotic and desmoplastic stroma, dearth of confirmatory diagnostic approaches and resistance to chemotherapeutics. This inimitable tumor microenvironment (TME) or desmoplasia with excessive extracellular matrix accumulation, create an extremely hypovascular, hypoxic and nutrient-deficient zone inside the tumor. To survive, grow and proliferate in such tough TME, pancreatic tumor and stromal cells transform their metabolism. Transformed glucose, glutamine, fat, nucleotide metabolism and inter-metabolite communication between tumor and TME in synergism, impart therapy resistance, and immunosuppression in PanCa. Thus, a finer knowledge of altered metabolism would uncover its metabolic susceptibilities. These unique metabolic targets may help to device novel diagnostic/prognostic markers and therapeutic strategies for better management of PanCa. In this review, we sum up reshaped metabolic pathways in PanCa to formulate detection and remedial strategies of this devastating disease.

References

Yin X, Xu R, Song J, Ruze R, Chen Y, Wang C . Lipid metabolism in pancreatic cancer: emerging roles and potential targets. Cancer Commun (Lond). 2022; 42(12):1234-1256. PMC: 9759769. DOI: 10.1002/cac2.12360. View

Ricciardiello F, Gang Y, Palorini R, Li Q, Giampa M, Zhao F . Hexosamine pathway inhibition overcomes pancreatic cancer resistance to gemcitabine through unfolded protein response and EGFR-Akt pathway modulation. Oncogene. 2020; 39(20):4103-4117. DOI: 10.1038/s41388-020-1260-1. View

Guillaumond F, Leca J, Olivares O, Lavaut M, Vidal N, Berthezene P . Strengthened glycolysis under hypoxia supports tumor symbiosis and hexosamine biosynthesis in pancreatic adenocarcinoma. Proc Natl Acad Sci U S A. 2013; 110(10):3919-24. PMC: 3593894. DOI: 10.1073/pnas.1219555110. View

Zhang L, Han L, He J, Lv J, Pan R, Lv T . A high serum-free fatty acid level is associated with cancer. J Cancer Res Clin Oncol. 2019; 146(3):705-710. PMC: 7039835. DOI: 10.1007/s00432-019-03095-8. View

Chen S, Ning B, Song J, Yang Z, Zhou L, Chen Z . Enhanced pentose phosphate pathway activity promotes pancreatic ductal adenocarcinoma progression via activating YAP/MMP1 axis under chronic acidosis. Int J Biol Sci. 2022; 18(6):2304-2316. PMC: 8990471. DOI: 10.7150/ijbs.69526. View

Zhao Y, Butler E, Tan M . Targeting cellular metabolism to improve cancer therapeutics. Cell Death Dis. 2013; 4:e532. PMC: 3613838. DOI: 10.1038/cddis.2013.60. View

Ying H, Kimmelman A, Lyssiotis C, Hua S, Chu G, Fletcher-Sananikone E . Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell. 2012; 149(3):656-70. PMC: 3472002. DOI: 10.1016/j.cell.2012.01.058. View

Qin C, Yang G, Yang J, Ren B, Wang H, Chen G . Metabolism of pancreatic cancer: paving the way to better anticancer strategies. Mol Cancer. 2020; 19(1):50. PMC: 7053123. DOI: 10.1186/s12943-020-01169-7. View

Olivares O, Mayers J, Gouirand V, Torrence M, Gicquel T, Borge L . Collagen-derived proline promotes pancreatic ductal adenocarcinoma cell survival under nutrient limited conditions. Nat Commun. 2017; 8:16031. PMC: 5504351. DOI: 10.1038/ncomms16031. View

10.

Sikdar N, Saha G, Dutta A, Ghosh S, Shrikhande S, Banerjee S . Genetic Alterations of Periampullary and Pancreatic Ductal Adenocarcinoma: An Overview. Curr Genomics. 2018; 19(6):444-463. PMC: 6128383. DOI: 10.2174/1389202919666180221160753. View

11.

Li Y, Zhao W, Wang Y, Wang H, Liu S . Extracellular vesicle-mediated crosstalk between pancreatic cancer and stromal cells in the tumor microenvironment. J Nanobiotechnology. 2022; 20(1):208. PMC: 9063273. DOI: 10.1186/s12951-022-01382-0. View

12.

Wang W, Cui J, Ma H, Lu W, Huang J . Targeting Pyrimidine Metabolism in the Era of Precision Cancer Medicine. Front Oncol. 2021; 11:684961. PMC: 8194085. DOI: 10.3389/fonc.2021.684961. View

13.

Park W, Chawla A, OReilly E . Pancreatic Cancer: A Review. JAMA. 2021; 326(9):851-862. PMC: 9363152. DOI: 10.1001/jama.2021.13027. View

14.

Vaziri-Gohar A, Zarei M, Brody J, Winter J . Metabolic Dependencies in Pancreatic Cancer. Front Oncol. 2019; 8:617. PMC: 6315177. DOI: 10.3389/fonc.2018.00617. View

15.

Unger K, Mehta K, Kaur P, Wang Y, Menon S, Jain S . Metabolomics based predictive classifier for early detection of pancreatic ductal adenocarcinoma. Oncotarget. 2018; 9(33):23078-23090. PMC: 5955422. DOI: 10.18632/oncotarget.25212. View

16.

Camelo F, Le A . The Intricate Metabolism of Pancreatic Cancers. Adv Exp Med Biol. 2021; 1311:77-88. PMC: 9703229. DOI: 10.1007/978-3-030-65768-0_5. View

17.

Ilic I, Ilic M . International patterns in incidence and mortality trends of pancreatic cancer in the last three decades: A joinpoint regression analysis. World J Gastroenterol. 2022; 28(32):4698-4715. PMC: 9476884. DOI: 10.3748/wjg.v28.i32.4698. View

18.

Menezes S, Okail M, Jalil S, Kocher H, Cameron A . Cancer-associated fibroblasts in pancreatic cancer: new subtypes, new markers, new targets. J Pathol. 2022; 257(4):526-544. PMC: 9327514. DOI: 10.1002/path.5926. View

19.

Muyinda I, Park J, Jang E, Yoo B . KRAS, A Prime Mediator in Pancreatic Lipid Synthesis through Extra Mitochondrial Glutamine and Citrate Metabolism. Int J Mol Sci. 2021; 22(10). PMC: 8150642. DOI: 10.3390/ijms22105070. View

20.

Lee S, Hong E, Jo E, Kim Z, Yim K, Woo S . Gossypol Induces Apoptosis of Human Pancreatic Cancer Cells via CHOP/Endoplasmic Reticulum Stress Signaling Pathway. J Microbiol Biotechnol. 2022; 32(5):645-656. PMC: 9628887. DOI: 10.4014/jmb.2110.10019. View